公开(公告)号：US20150313927A1

公开(公告)日：2015-11-05

申请号：US14647751

申请日：2013-11-27

申请人： Mark John Berry ,  Mark Ian Fowler ,  Alan David Heath

发明人： Mark John Berry ,  Mark Ian Fowler ,  Alan David Heath

IPC分类号： A61K31/7048 ,  A23L1/30 ,  A23L2/52 ,  A61K31/05

CPC分类号： A61K31/7048 ,  A23L2/52 ,  A23L33/10 ,  A23L33/105 ,  A23V2002/00 ,  A23V2200/00 ,  A61K31/05 ,  A61K31/7034 ,  A61K2300/00 ,  A23V2200/328 ,  A23V2250/2116

摘要： Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. In a first aspect of the invention, an edible composition is provided, in the form of a single serving of one or more unit dosages, wherein the edible composition comprises 20-2000, preferably 30-1000, most preferably 40-500 mg a 3,5-dihydroxy-trans-stilbene and 10-2000, preferably 20-1000, most preferably 40-500 mg flavonoid mono-glucoside or dihydrochalcone monoglucoside.

摘要翻译： 可食用的碳水化合物如蔗糖或淀粉的食物或膳食会增加餐后血糖浓度。 重复的餐后血浆葡萄糖“尖峰”与发展为II型糖尿病的风险增加有关。 未调节的血糖偏移是不合需要的，血液中餐后葡萄糖浓度的任何减少或“钝化”都是潜在有益的。 本发明涉及通过协同抑制活性钠葡萄糖共转运蛋白1（SGLT1）和被动葡萄糖转运蛋白2（GLUT2）导致餐后葡萄糖峰值变平或变平的延迟肠葡萄糖摄取的食用组合物。 在本发明的第一方面，提供了一种单一剂量单一形式的可食用组合物，其中可食用组合物包含20-2000，优选30-1000，最优选40-500mg a 3 ，5-二羟基 - 反式 - 二苯乙烯和10-2000，优选20-1000，最优选40-500mg类黄酮单葡萄糖苷或二氢查耳酮单葡萄糖苷。

公开(公告)号：US09387219B2

公开(公告)日：2016-07-12

申请号：US14122355

申请日：2012-05-29

申请人： Mark John Berry ,  Mark Ian Fowler ,  Alan David Heath

发明人： Mark John Berry ,  Mark Ian Fowler ,  Alan David Heath

IPC分类号： A61K31/7034 ,  A61K31/7048 ,  A23L1/30 ,  A61K31/352 ,  A61K31/715

CPC分类号： A61K31/7048 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/352 ,  A61K31/7034 ,  A61K31/715 ,  A23V2200/15 ,  A23V2200/328

摘要： Foods or meals high in available carbohydrate such as sucrose or starch increase post-prandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. Thus in a first aspect of the invention, an edible composition is provided, the composition comprising at least 5% dry weight at least one flavonoid aglycone and at least 5% dry weight at least one flavonoid glucoside, wherein the flavonoid glucoside is at least 20%, preferably at least 40%, most preferably at least 60% more resistant to hydrolysis by lactase phloridzin hydrolase than quercetin-4-glucoside, and wherein the flavonoid aglycone is a GLUT 2 inhibitor and the flavonoid glucoside is a SGLT 1 inhibitor.

摘要翻译： 可食用的碳水化合物如蔗糖或淀粉的食物或膳食会增加餐后血糖浓度。 重复的餐后血浆葡萄糖“尖峰”与发展为II型糖尿病的风险增加有关。 未调节的血糖偏移是不合需要的，血液中餐后葡萄糖浓度的任何减少或“钝化”都是潜在有益的。 本发明涉及通过协同抑制活性钠葡萄糖共转运蛋白1（SGLT1）和被动葡萄糖转运蛋白2（GLUT2）导致餐后葡萄糖峰值变平或变平的延迟肠葡萄糖摄取的食用组合物。 因此，在本发明的第一方面中，提供了一种可食用组合物，所述组合物包含至少5％干重至少一种类黄酮糖苷配基和至少5％干重至少一种类黄酮糖苷，其中所述类黄酮糖苷为至少20 ％，优选至少40％，最优选至少60％，比槲皮素-4-葡萄糖苷更能抵抗乳糖酶花青素水解酶的水解，其中黄酮糖苷配基是GLUT2抑制剂，类黄酮糖苷是SGLT 1抑制剂。

公开(公告)号：US20140107052A1

公开(公告)日：2014-04-17

申请号：US14122355

申请日：2012-05-29

申请人： Mark John Berry ,  Mark Ian Fowler ,  Alan David Heath

发明人： Mark John Berry ,  Mark Ian Fowler ,  Alan David Heath

IPC分类号： A61K31/7048 ,  A61K31/7034

CPC分类号： A61K31/7048 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/352 ,  A61K31/7034 ,  A61K31/715 ,  A23V2200/15 ,  A23V2200/328

摘要： Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. Thus in a first aspect of the invention, an edible composition is provided, the composition comprising at least 5% dry weight at least one flavonoid aglycone and at least 5% dry weight at least one flavonoid glucoside, wherein the flavonoid glucoside is at least 20%, preferably at least 40%, most preferably at least 60% more resistant to hydrolysis by lactase phloridzin hydrolase than quercetin-4-glucoside, and wherein the flavonoid aglycone is a GLUT 2 inhibitor and the flavonoid glucoside is a SGLT 1 inhibitor.

摘要翻译： 可食用的碳水化合物如蔗糖或淀粉的食物或膳食会增加餐后血糖浓度。 重复的餐后血浆葡萄糖“尖峰”与发展为II型糖尿病的风险增加有关。 未调节的血糖偏移是不合需要的，血液中餐后葡萄糖浓度的任何减少或“钝化”都是潜在有益的。 本发明涉及通过协同抑制活性钠葡萄糖共转运蛋白1（SGLT1）和被动葡萄糖转运蛋白2（GLUT2）导致餐后葡萄糖峰值变平或变平的延迟肠葡萄糖摄取的食用组合物。 因此，在本发明的第一方面中，提供了一种可食用组合物，所述组合物包含至少5％干重至少一种类黄酮糖苷配基和至少5％干重至少一种类黄酮糖苷，其中所述类黄酮糖苷为至少20 ％，优选至少40％，最优选至少60％，比槲皮素-4-葡萄糖苷更能抵抗乳糖酶花青素水解酶的水解，其中黄酮糖苷配基是GLUT2抑制剂，类黄酮糖苷是SGLT 1抑制剂。